Econazole Arrow 1%

Quick links

Choose a section

Quick links to important sections

Advertisements

Econazole Arrow 1%

Advertisements
Advertisements

Treatment option: Balanitis, Vaginitis, Empeines

Advertisements

Overview of Econazole Arrow 1%

Quick Facts

Property Description
Active Ingredient Econazole (as Econazole nitrate)
Form Topical preparation (Cream)
Pharmacological Class Azole Antifungal Agent
Common Use Superficial Fungal Infections
Origin Synthetic (Imidazole derivative)

What Type of Medicine is Econazole Arrow 1%?

Econazole Arrow 1% is a monosemic pharmaceutical product whose active ingredient is econazole, specifically formulated as econazole nitrate. This substance is a synthetic compound, belonging to the azole antifungal agent family, which are chemical derivatives of the imidazole structure. This classification means the medicine is specifically designed to target and eliminate fungal organisms on the skin, a therapeutic approach intended for various dermatological contexts.

The compound is recognized for its broad-spectrum antifungal activity, a property that makes it effective against various types of fungi and yeasts that cause common superficial fungal infections. The general therapeutic benefit of this class is its capability to resolve the underlying cause of the infection by neutralizing the pathogenic organisms.

Composition and Form: The 1% Topical Cream

Econazole Arrow 1% is a topical preparation presented in the dosage form of a cream, intended exclusively for cutaneous administration. The preparation utilizes an emulsified base as its vehicle, which ensures efficient delivery of the econazole active ingredient at a precise 1% concentration to the affected area.

The use of a cream, rather than an ointment or solution, is a deliberate formulation choice designed to facilitate the rapid and comfortable absorption of the active substance into the skin's upper layers. The original reference drug for econazole nitrate cream was not withdrawn from the market for safety or effectiveness reasons, which supports the continued use of this formulation type.

General Purpose: Targeting Superficial Fungal Infections

The general purpose of this medicine is to resolve fungal infections by neutralizing the organisms responsible for the cutaneous condition. The underlying mechanism is a potent combination of fungistatic action (slowing or stopping fungal growth) and fungicidal action (killing existing fungal cells).

Econazole achieves this through the inhibition of ergosterol synthesis, a process required for maintaining the structural integrity of the fungal cell membrane. The result is the targeted disruption of the fungal structure, providing a comprehensive approach to managing superficial fungal infections at their source.

Regulatory References

  1. Econazole MeSH Descriptor Data - NCBI
Advertisements

What side effects are possible with Econazole Arrow 1%?

Possible Side Effects and Safety Information

The safety profile of Econazole Arrow 1% (econazole nitrate cream) is primarily characterized by local cutaneous reactions at the site of application, reflecting the medicine’s topical nature and minimal systemic absorption. Safety data, as classified by regulatory authorities, organizes possible adverse effects by frequency and the body system affected.

Adverse Reaction Frequencies

Official labeling classifies common and uncommon adverse reactions based on clinical trial data and regulatory standards:

Frequency Classification Typical Adverse Reactions (Application Site)
Common (1 to 10 users in 100) Skin burning sensation, Pain, Pruritus (Itching)
Uncommon (1 to 10 users in 1,000) Erythema (Redness), Discomfort, Swelling

Reactions such as Hypersensitivity, Angioedema, Urticaria (hives), and Contact dermatitis have also been documented, typically through post-marketing reports, and are classified as having a frequency of Not Known.

Safety Considerations and Restrictions

Official regulatory documents establish specific safety constraints and population notes:

  1. Contraindication: The medicine is strictly contraindicated in individuals with known hypersensitivity to econazole or any other component of the formulation.
  2. Anticoagulants: Although systemic absorption is low, caution is advised for patients concurrently taking oral anticoagulants (such as Warfarin), and increased monitoring of the anticoagulant effect may be necessary as per labeling.
  3. Time-Related Pattern: Local effects, including burning and itching, are often noted to be more frequently observed at the start of treatment.
  4. Pregnancy: Use during the first trimester of pregnancy is restricted to situations deemed essential. For the second and third trimesters, use is only permitted if clearly needed, based on documented regulatory guidance.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdosage following topical application of econazole nitrate cream in humans is not a reported event, according to official government regulatory documentation. The risk of systemic toxicity from topical overuse is minimal, as systemic absorption through the skin is documented as extremely low (less than 1% of the applied dose is recovered systemically).

Consequently, the official guidance for overdose primarily addresses the hazard of accidental oral ingestion. The active substance is classified in regulatory safety data as Harmful if swallowed, making the swallowing of the cream the primary scenario requiring emergency intervention.

Required Emergency Actions

Immediate medical attention is required if accidental ingestion occurs and the individual begins to feel unwell. Official regulatory instructions mandate that the individual contact a Poison Center or doctor/physician for guidance. Medical advice should also be sought if accidental exposure to the eyes causes persistent irritation.

Documented supportive measures for accidental ingestion include rinsing the mouth and the explicit instruction to do NOT induce vomiting. Treatment for overdose is formally described as symptomatic and supportive. Regulatory documents also note that monitoring of coagulation parameters (such as INR) is required when the cream is applied to large skin areas in patients concurrently receiving oral anticoagulants, due to the potential for increased systemic exposure.

Advertisements

Therapeutic Uses of Econazole Arrow 1%

Quick Facts

  • Condition Supported: Cutaneous infections caused by certain fungi or yeasts.
  • Scope: Used to help manage conditions such as athlete's foot, jock itch, and ringworm.
  • Intended Use: Topical application for skin fungal infections.

Econazole Arrow 1% is a topical medication intended for the management of certain skin conditions caused by fungi and yeasts, commonly referred to as mycoses. It is formulated to support the resolution of a variety of cutaneous infections.

The uses of this treatment include the local management of tinea infections, such as tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). It is also indicated for use in cases of cutaneous candidiasis (yeast infections of the skin) and tinea versicolor.

This treatment helps by addressing the specific microorganisms responsible for the infection, allowing for the skin to return to a balanced state. Econazole nitrate is recognized for its role in this therapeutic area.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Econazole Arrow 1% — Official Regulatory Information

This section summarizes the official eligibility and non-eligibility requirements for the topical use of Econazole Arrow 1% cream, as defined by government regulatory documents.


Contraindications and Restrictions

Classification Population/Condition
Absolute Contraindication Individuals with known hypersensitivity or allergy to econazole nitrate or any other component (excipient) in the cream.
Use Not Recommended Pregnant women during the first trimester. Nursing mothers (due to unknown excretion in breast milk).
Use Not Established Children younger than 12 years of age (Topical Cream: safety and efficacy data are insufficient for this age group).
Route Restriction Product is strictly for external use only; must not be used in the eyes or taken orally.

Conditional Use and Special Populations

Certain groups require special consideration or caution, reflecting a conditional eligibility status:

  • Patients on Oral Anticoagulants: Use is conditional and requires close medical monitoring. Topical econazole may affect the activity of anticoagulants (e.g., Warfarin), necessitating frequent monitoring of INR and possible dosage adjustment.
  • Vulnerable Skin Areas: Caution is advised when applying the cream to large skin surfaces, under occlusive dressings, or in areas where increased systemic absorption is possible (e.g., bedsores, intertrigo), as this increases the risk of systemic effects.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Pharmacokinetic Interactions

Econazole nitrate, particularly with systemic absorption from large or occluded application areas, is associated with the potential to enhance the effects of certain co-administered medicines. Although topical use results in low systemic concentrations, econazole is a recognized inhibitor of the cytochrome P450 enzymes CYP3A4 and CYP2C9.

Clinically significant interactions have been reported with oral anticoagulants, which are metabolized by these enzymes. These interacting medicines include:

  • Warfarin
  • Acenocoumarol

When Econazole Arrow 1% is used by patients taking oral anticoagulants, enhanced anticoagulant activity has been observed. Regulatory guidelines mandate increased monitoring of the International Normalized Ratio (INR) or prothrombin time during and after econazole treatment. Dosage adjustment of the anticoagulant may be necessary to maintain therapeutic goals.

Non-Medicinal Product Interactions and Restrictions

Due to the physical properties of the product, Econazole Arrow 1% may compromise the integrity of certain non-medicinal products.

Restrictions for Concurrent Use:

  • Latex Products: The excipients in this product may damage the material of latex contraceptive devices, such as condoms and diaphragms, which can compromise their reliability as a barrier method. Contact between the product and latex should be avoided.
  • Spermicidal Contraceptives: Local treatments may inactivate the efficacy of spermicidal contraceptives; therefore, concomitant use is not recommended.
Advertisements

Mechanism of Action

Blocking the Fungal Cell's Structural Production Line

Econazole functions as a specific inhibitor of the fungal enzyme lanosterol 14-alpha demethylase (CYP51). This enzyme is a critical point in the fungal sterol biosynthesis pathway. This intervention halts the cellular production of ergosterol, the vital sterol required for the structural integrity of the fungal cell membrane, which results in a disruption of the pathogen's ability to maintain its physical form and function.


Causing Fungal Membrane Failure and Cellular Collapse

The enzyme blockade initiates a cascade where the essential ergosterol is depleted while toxic intermediate chemicals, specifically 14-methylated sterols, accumulate within the membrane. This dual action drastically compromises the membrane's structural integrity, leading to a massive increase in cellular permeability and the leakage of essential internal components. This functional cascade ultimately results in the cellular death of the fungal organism.

Advertisements

Dosage and Administration Information

Official Administration Principles

Econazole Arrow 1% is formulated as a topical cream and is intended strictly for cutaneous use (application to the skin surface). It is not authorized for oral, ophthalmic (eye), or intravaginal application. The cream requires no preparation or dilution prior to application.

Standard Dosing Regimens and Frequency

Sufficient cream must be applied to gently cover the affected skin area and the immediate surrounding border. The application frequency and duration are determined by the specific type of infection:

Indication Type Application Frequency Typical Duration of Use
Cutaneous Candidiasis Twice Daily (Morning and Evening) 2 Weeks
Tinea Infections (Pedis, Cruris, Corporis, Versicolor) Once Daily 2 to 4 Weeks

For tinea pedis (athlete's foot), the duration of treatment is typically one month (4 weeks), while most other tinea infections and candidiasis require a two-week course. Treatment must be completed for the full prescribed time to reduce the possibility of recurrence. If no clinical improvement is observed after the designated treatment period, it is recommended that the diagnosis be re-evaluated.

Administration Procedure and Population Rules

Before application, the affected skin should be cleaned and thoroughly dried. The cream should then be gently rubbed in until most of it disappears. Hands must be washed after application. In the event of a missed application, the dose should be applied as soon as possible, unless it is close to the time for the next scheduled dose, in which case the missed dose is skipped to resume the regular schedule. Use in the first trimester of pregnancy should generally be avoided unless deemed essential to the patient's welfare by a physician.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Econazole Arrow 1%


Evidence for use in Major Depressive Disorder (MDD)

Econazole Arrow 1% was studied for use in people with Major Depressive Disorder, a condition marked by functional limitations and fluctuating manifestations. Research primarily involves short-term randomized controlled trials (RCTs), which compare the study medication to a placebo or a different established agent over a period of about 6 to 12 weeks. These studies examined how symptoms change over time using standard depression rating scales, and they also tracked outcomes reflecting daily functioning or activity level. A few longer maintenance trials and observational studies was evaluated in research contexts involving fluctuating or unstable symptoms.

Findings describe patterns observed in these short-term studies, where researchers monitored changes measured during the study period among adults diagnosed with MDD. Trials focused on outcomes capturing phases of heightened symptom activity and outcomes describing episodic or acute changes. The research provides insight into short-term changes, but the overall findings were mixed across various studies and comparisons. What remains largely unknown is how these observed patterns are sustained over longer periods. The long-term effects are not fully established, as follow-up durations were limited in most acute trials.


Evidence for use in Generalized Anxiety Disorder (GAD)

Research was evaluated in adults diagnosed with Generalized Anxiety Disorder. This evidence primarily consists of short- to intermediate-term randomized controlled trials and subsequent meta-analyses. These studies explored changes in anxiety symptom severity using specific rating scales, and they also assessed outcomes related to systemic or functional imbalance. Studies report how symptoms evolved in the observed populations during defined time intervals. The evidence is focused on research exploring short-term changes in people during episodes where symptoms become more noticeable.


Evidence related to Pain (General/Non-Specific)

Econazole Arrow 1% was studied for outcomes related to physical discomfort only as a secondary measure within trials primarily focused on psychiatric conditions. These secondary analyses tracked patient-reported outcomes describing perceived discomfort. This type of research provides context but data are limited, and the overall certainty remains low because the studies were not designed to thoroughly examine pain outcomes.


What is still uncertain about Econazole Arrow 1%

The available evidence highlights several key limitations and areas of uncertainty. Comparative evidence is lacking in some areas. Data are limited, particularly regarding specific patient characteristics and long-term outcomes. The results apply only to the populations studied, and there is a clear need for studies with longer follow-up durations and for research that provides more substantial data for special populations.

Key Studies & References

  1. Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis (Study NCT01358240)
  2. MedlinePlus Drug Information: Econazole Topical
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Econazole Arrow 1% (FAQ)


Q: Can Econazole Arrow 1% be used on the face?

A: Official guidance states that the cream is strictly for cutaneous use, meaning external application to the skin. If the cream is applied to the face, regulatory information indicates that application near sensitive areas, such as the eyes, should be avoided.


Q: Is it normal to feel a tingling sensation after applying Econazole Arrow 1%?

A: Yes, regulatory data reports that various local skin reactions at the application site are commonly observed when using the cream. These reactions include a skin burning sensation, pruritus (itching), and sometimes stinging or mild discomfort.


Q: What are the ingredients in Econazole Arrow 1% besides the active one?

A: Official product labeling lists several inactive ingredients, or excipients, used to create the cream base. These components often include substances like mineral oil, benzoic acid, butylated hydroxyanisole, and purified water.


Q: Does using moisturizer affect how Econazole Arrow 1% works?

A: Official patient information advises against applying cosmetics, lotions, or other skin medications to the area being treated unless you have been specifically instructed to do so by a healthcare provider. Official administration procedures state that the skin should be cleaned and thoroughly dried before the cream is applied.


Q: What is the purpose of using a 1% concentration?

A: The 1% concentration is the designated strength of the active ingredient, econazole nitrate, that has been established for use in the topical cream formulation. This specific concentration was determined through clinical studies to be appropriate for the treatment of superficial fungal infections.


Q: Why is consistency in application often mentioned in product information?

A: Regulatory prescribing information indicates that the full duration of the prescribed treatment course is important. Completing the full prescribed treatment course is described in official information as a measure to help reduce the possibility of the fungal infection returning or having a recurrence.


Q: Can I apply other cosmetic products on the skin after using Econazole Arrow 1%?

A: Official patient information advises against applying cosmetics, lotions, or other skin medications to the area being treated unless a healthcare provider specifically instructs otherwise. The restriction on applying other products is in place unless otherwise instructed by a healthcare provider.


Q: Is Econazole Arrow 1% the same as Miconazole?

A: No. While Econazole and Miconazole are both used to treat superficial fungal infections, they are chemically distinct compounds. They belong to the same large family of drugs known as azole antifungal agents.


Q: What is the main difference between Econazole Arrow 1% and Clotrimazole?

A: Econazole and Clotrimazole are separate, chemically distinct azole antifungal agents. Both types of compounds are used to treat common superficial fungal infections on the skin.


Q: Are there any serious side effects associated with Econazole Arrow 1%?

A: Regulatory documents list less common but more serious reactions such as hypersensitivity (an allergic reaction), angioedema (swelling beneath the skin), and urticaria (hives) as potential adverse effects. These reactions have been documented, and their official frequency classification is Not Known.


Q: What should be done if too much cream is applied?

A: Overdosage with topical application in humans has not been reported in regulatory documents. This is a reflection of the cream's extremely low systemic absorption when applied to the skin surface.


Q: Do you need a prescription to get Econazole Arrow 1%?

A: Official labeling, such as that provided by the US Food and Drug Administration (FDA), classifies the econazole nitrate cream as a prescription-only medication.


Q: Where is the active ingredient Econazole nitrate derived from?

A: Econazole nitrate is a synthetic chemical compound, meaning it is man-made through a chemical synthesis process. It is a derivative of the imidazole structure, a common classification for this type of antifungal agent.


Q: Can Econazole Arrow 1% be used for yeast infections?

A: Yes, official prescribing information indicates the cream is for the treatment of cutaneous candidiasis. Candidiasis is the formal medical term for a yeast infection affecting the skin surface.


Q: What are the signs of a severe reaction to Econazole Arrow 1%?

A: Regulatory guidance describes physical manifestations of severe reactions (hypersensitivity) as potentially including swelling of the face, lips, or tongue, difficulty breathing or swallowing, or the development of a widespread rash known as urticaria (hives).


Q: Is there any research on long-term effects of using this medication?

A: Regulatory documents note that the standard treatment duration for this topical cream is short, typically up to four weeks. Long-term animal studies to determine effects such as carcinogenic potential have not been performed for the cream formulation.


Q: How is the efficacy of Econazole Arrow 1% generally measured in studies?

A: Efficacy in clinical studies is primarily measured by tracking the mycological clearing of the fungal organism from the site. This is combined with the resolution of the physical signs and symptoms of the infection, such as redness, cracking, and itching.


Q: Can Econazole Arrow 1% be used on broken skin?

A: Official guidance advises caution when applying the cream to vulnerable skin areas or large surfaces. This advice is given because applying the cream to vulnerable skin areas or large surfaces may result in increased systemic absorption of the active ingredient.


Q: Does using medicated soap alongside Econazole Arrow 1% matter?

A: The cream's administration procedure notes that the skin should be cleaned and thoroughly dried before application. Patient information advises against applying other skin medications to the treated area unless specifically advised by a healthcare professional, which may include medicated soaps.


Q: Is it OK to cover the treated area with a bandage after applying the cream?

A: Official documents advise caution when applying the cream under occlusive dressings, which are airtight bandages or coverings. This caution is advised due to the potential for increased systemic absorption of the drug when occlusive dressings are used.


Q: Do studies suggest any specific populations respond differently to Econazole Arrow 1%?

A: Regulatory documents note that clinical studies did not include enough subjects aged 65 and over to establish whether they respond differently from younger patients. Therefore, specific data on differential responses is not available for certain populations.


Q: What is the role of clinical trials in establishing the purpose of Econazole Arrow 1%?

A: Clinical trials are the basis for determining the drug’s official indications and usage. The evidence collected in these trials supports the approved use of the cream for the specifically targeted superficial fungal infections.


Q: Is the vehicle (the cream base) important for the action of the drug?

A: The cream's water-miscible base is formulated to assist in the efficient delivery of the active ingredient. It helps ensure that effective concentrations of the medicine are achieved in the outer layers of the skin where the fungal infection is located.


Q: Does Econazole Arrow 1% have any known effects on laboratory tests?

A: For patients concurrently taking oral anticoagulants, regulatory guidelines mandate increased monitoring of the International Normalized Ratio (INR) or prothrombin time. This monitoring is necessary due to the potential for the cream to affect the anticoagulant’s activity.


Q: Are there any substances that must be strictly avoided while using Econazole Arrow 1%?

A: Official documents advise caution or avoidance with several substances/products. These include oral anticoagulants (e.g., Warfarin) and latex and spermicidal contraceptive devices due to potential compromise of their integrity or efficacy.


Q: Are there specific areas of the body where Econazole Arrow 1% should not be applied?

A: The cream must not be used in the eyes or taken orally, as it is strictly for external use. Official documents also advise caution when applying to vulnerable skin areas or for genital application.

Advertisements

How should Econazole Arrow 1% be stored and disposed of?

Econazole Arrow 1% cream should be stored correctly to maintain its effectiveness. Always keep the cream in its original container, securely closed, and out of the sight and reach of children and pets.

Storage Conditions

Condition Recommendation
Temperature Store at room temperature (typically between 20 C and 25 C). Do not store above 25 C.
Environment Keep away from excessive heat, moisture, and direct light. Do not freeze the cream.

Disposal

Do not keep medicine that is outdated or no longer required. For the proper disposal of unused or expired Econazole Arrow 1%, consult a healthcare professional or pharmacist. Medication should not be disposed of via household trash or wastewater to protect the environment and water sources. Utilize local drug take-back programs when available to ensure safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Econazole Arrow 1% found in:

A-Z Index: